skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Improving cancer treatment with cyclotron produced radionuclides

Abstract

This report describes the author's continuing long term goal of promoting nuclear medicine applications by improving the scientific basis for tumor diagnosis treatment and treatment follow-up based on the use of cyclotron produced radiotracers in oncology. The program has 3 interactive components: Radiochemistry /Cyclotron; Pharmacology; and Immunology. An essential strategy is as follows: novel radionuclides and radiotracers developed in the Radiochemistry/Cyclotron section under the DOE grant during the 1989--1992 grant period, will be employed in the Pharmacology and Immunology sections of the DOE grant during the 1992--1995 grant period. The development of novel radionuclides and tracers is of course useful in and of itself, but their utility is greatly enhanced by the interaction with the immunology and pharmacology components of the program.

Authors:
Publication Date:
Research Org.:
Sloan-Kettering Inst. for Cancer Research, New York, NY (United States)
Sponsoring Org.:
USDOE; USDOE, Washington, DC (United States)
OSTI Identifier:
7262962
Report Number(s):
DOE/ER/60407-7
ON: DE92040310
DOE Contract Number:
FG02-86ER60407
Resource Type:
Technical Report
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; GALLIUM 66; NUCLEAR MEDICINE; IODINE 124; URIDINE; DIAGNOSTIC USES; CYCLOTRONS; FLUORINE 18; POSITRON COMPUTED TOMOGRAPHY; PROGRESS REPORT; RADIOCHEMISTRY; RADIOPHARMACEUTICALS; ACCELERATORS; AZINES; BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; CHEMISTRY; COMPUTERIZED TOMOGRAPHY; CYCLIC ACCELERATORS; DAYS LIVING RADIOISOTOPES; DIAGNOSTIC TECHNIQUES; DOCUMENT TYPES; DRUGS; ELECTRON CAPTURE RADIOISOTOPES; EMISSION COMPUTED TOMOGRAPHY; FLUORINE ISOTOPES; GALLIUM ISOTOPES; HETEROCYCLIC COMPOUNDS; HOURS LIVING RADIOISOTOPES; HYDROXY COMPOUNDS; INTERMEDIATE MASS NUCLEI; IODINE ISOTOPES; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; LABELLED COMPOUNDS; LIGHT NUCLEI; MEDICINE; NANOSEC LIVING RADIOISOTOPES; NUCLEI; NUCLEOSIDES; NUCLEOTIDES; ODD-ODD NUCLEI; ORGANIC COMPOUNDS; ORGANIC NITROGEN COMPOUNDS; PYRIMIDINES; RADIOISOTOPES; RIBOSIDES; TOMOGRAPHY; URACILS; USES; 550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)

Citation Formats

Larson, S.M. Finn, R.D.. Improving cancer treatment with cyclotron produced radionuclides. United States: N. p., 1992. Web. doi:10.2172/7262962.
Larson, S.M. Finn, R.D.. Improving cancer treatment with cyclotron produced radionuclides. United States. doi:10.2172/7262962.
Larson, S.M. Finn, R.D.. Tue . "Improving cancer treatment with cyclotron produced radionuclides". United States. doi:10.2172/7262962. https://www.osti.gov/servlets/purl/7262962.
@article{osti_7262962,
title = {Improving cancer treatment with cyclotron produced radionuclides},
author = {Larson, S.M. Finn, R.D.},
abstractNote = {This report describes the author's continuing long term goal of promoting nuclear medicine applications by improving the scientific basis for tumor diagnosis treatment and treatment follow-up based on the use of cyclotron produced radiotracers in oncology. The program has 3 interactive components: Radiochemistry /Cyclotron; Pharmacology; and Immunology. An essential strategy is as follows: novel radionuclides and radiotracers developed in the Radiochemistry/Cyclotron section under the DOE grant during the 1989--1992 grant period, will be employed in the Pharmacology and Immunology sections of the DOE grant during the 1992--1995 grant period. The development of novel radionuclides and tracers is of course useful in and of itself, but their utility is greatly enhanced by the interaction with the immunology and pharmacology components of the program.},
doi = {10.2172/7262962},
journal = {},
number = ,
volume = ,
place = {United States},
year = {Tue Aug 04 00:00:00 EDT 1992},
month = {Tue Aug 04 00:00:00 EDT 1992}
}

Technical Report:

Save / Share: